NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

The FDA recently (October 2022) released new draft guidance titled: Tissue Agnostic Drug Development in Oncology - Guidance for Industry

A tissue agnostic oncology drug can therefore be used to treat multiple types of cancer (e.g., colorectal, thyroid, and breast cancers) with the targeted molecular alteration (e.g., either the same targeted molecular alteration or targeted molecular alterations affecting a single pathway).

https://www.fda.gov/media/162346/download

This is great news for NWBio, for the further development of its DCVax-L and DCVax Direct vaccine platforms, that will target all solid tumor cancers, both operable and inoperable.